Mechanism of Action, Resistance, Interaction, Pharmacokinetics, Pharmacodynamics, and Safety of Fostemsavir Publisher Pubmed



Heidary M^{1, 2} ; Shariati S^{3, 4} ; Nourigheimasi S⁵ ; Khorami M⁶ ; Moradi M⁷ ; Motahar M⁷ ; Bahrami P⁴ ; Akrami S^{7, 8, 9} ; Kaviar VH¹⁰
Source: BMC Infectious Diseases Published:2024

Abstract

The Food and Drug Administration (FDA) has licensed many antiretroviral medications to treat human immunodeficiency virus type 1 (HIV-1), however, treatment options for people with multi-drug resistant HIV remain limited. Medication resistance, undesirable effects, prior tolerance, and previous interlacement incapacity to deliver new drug classes all lead to the requirement for new medication classes and drug combination therapy. Fostemsavir (FTR) is a new CD-4 attachment inhibitor medicine that was recently authorized by the United States FDA to treat HIV-1. In individuals with multidrug-resistant (MDR) HIV-1, FTR is well tolerated and virologically active. According to recent investigations, drug combination therapy can positively affect MDR-HIV. The mechanism of action, resistance, interaction, pharmacokinetics, pharmacodynamics, and safety of FTR has been highlighted in this review. © The Author(s) 2024.